Objective: We aimed to investigate whether Serum Prolidase Activity (SPA) levels could be used as a potential diagnostic and/or prognostic biomarker in Acute Ischemic Stroke (AIS) patients or not.
Materials and Methods: SPA levels were prospectively evaluated in 37 patients aged between 20 and 85 y who were admitted within 24 h of the onset of AIS. The control group included 37 healthy volunteers of similar age without any disease.
Results: In AIS patients, mean SPA was significantly higher compared to healthy controls (1331 ± 399 pg/ml vs. 1169 ± 221 pg/ml, respectively; p=0.035). SPA was not correlated with age, gender, hypertension, diabetes, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, hemoglobin, c-reactive protein, or hemoglobin A1c levels (p>0.05 for all comparisons). However, patients with new diagnostic atrial fibrillation had higher levels of prolidase acitvity than the others (1647 ± 403 pg/ml vs. 1270 ± 384 pg/ml, p=0.032). SPA levels were also uncorrelated with National Institutes of Health Stroke Scale, infarct volume, Trial of Org 10172 and the Oxfordshire Community Stroke Project classifications, and duration of hospitalization (p>0.05, for all comparisons).
Conclusions: Increased levels of serum prolidase enzyme activity may be an independent predictor of AIS and may contribute to stroke pathophysiology. However, further studies with larger populations are needed to reveal the role of SPA in AIS.